trending Market Intelligence /marketintelligence/en/news-insights/trending/A-51PmRDEl_-Zk_XvOnsTA2 content esgSubNav
In This List

Dimerix to raise A$2M for the development of orphan drug

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Dimerix to raise A$2M for the development of orphan drug

Dimerix Ltd. is looking to raise A$2 million to fund the development of DMX-200 as a potential treatment of chronic kidney disease.

The company said it received commitments for 333,333,333 new shares at 0.6 Australian cent apiece, with closing expected Feb. 4.

Westar Capital Ltd. acted as lead manager to the offer.

As of Jan. 24, US$1 was equivalent to A$1.32.